General information
InflaRx N.V.
Winzerlaer Str. 2
07745 Jena, Thuringia
Germany
Contact person: Niels C. Riedemann, Chief Executive Officer, Board Executive Director
Company main phone: +49 (3641) 508180
Company main fax: +49 (3641) 508181
Website: https://www.inflarx.de
Year founded: | 2007
|
Source of foundation: | Independent foundation |
No. of employees: |
Worldwide: 62 |
Corporate description / mission:
InflaRx is a clinical-stage biopharmaceutical company focused on applying the proprietary anti-C5a technology to discover and develop potent and specific inhibitors of C5a. Complement C5a is a powerful inflammatory mediator involved in the progression of a wide variety of autoimmune and other inflammatory diseases. InflaRx’s lead product candidate, vilobelimab, is a novel, intravenously delivered, first-in-class, anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical studies in different indications.
State of ownership: Publicly listed on stock exchange
Headquarters: HQ: Yes
IPO (year): 2017
Categorization
Sector: |
- Biotechnology - Therapeutics and Diagnostics
|
Subsector: |
- Anti-infectives
- Antibodies
- Small molecules
|
Primary therapeutic areas: |
- Diseases of the blood and blood-forming organs & immune disorders / hematology / immunology
- Infectious and parasitic diseases / infectiology / parasitology
- Neoplasms / cancer / oncology
- Skin and subcutaneous tissue / dermatology
- Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified
|
Business model: |
- In-licensing
- Manufacturer
- R&D
- Supplier / Distributor
|
Customer segments: |
- Hospitals
- Large biotech & big pharma
- Physicians / doctors
- Small biotech
|
Distribution: |
- Indirect (independent dealer)
|
Summary Products / Services / Technologies
Number of Biotech Products
Pre-clinical: | 1 | |
Phase I: | 1 | |
Phase II: | 1 | |
Phase III: | 2 | |
On the market: | 1 | |
Description of products:
Vilobelimab (IFX-1)
IFX-2
INF904
Technology used:
Anti C5a Technology
Financing details
Fiscal year (end of) 2023
Revenues: | USD 0.07M | |
R&D expenses: | USD 43.48M | |
Cash: | USD 13.83M | |
Total liabilities: | USD 19.09M | |
No. of shares: | 58'883'300 | |
Market cap. / valuation: | USD 88.17M | |